Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.

about

Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.

Item

http://www.wikidata.org/entity/Q49517068

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Differential presentation and ...... t cancer over time: 1990-2010.

@en

Differential presentation and ...... t cancer over time: 1990-2010.

@nl

type

Item

label

Differential presentation and ...... t cancer over time: 1990-2010.

@en

Differential presentation and ...... t cancer over time: 1990-2010.

@nl

prefLabel

Differential presentation and ...... t cancer over time: 1990-2010.

@en

Differential presentation and ...... t cancer over time: 1990-2010.

@nl

P1476

Differential presentation and ...... t cancer over time: 1990-2010.

@en

P2093

Henry G Kaplan

http://www.w3.org/2001/XMLSchema#string

Judith A Malmgren

http://www.w3.org/2001/XMLSchema#string

Mary K Atwood

http://www.w3.org/2001/XMLSchema#string

Musa Mayer

http://www.w3.org/2001/XMLSchema#string

P2860

Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Increase in mammography detected breast cancer over time at a community based regional cancer center: a longitudinal cohort study 1990-2005

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer

Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.

P2888

s10549-017-4529-5

P304

579-590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-017-4529-5

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

167

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092244454

http://www.w3.org/2001/XMLSchema#string

P698

29039120

http://www.w3.org/2001/XMLSchema#string

P932

5790843

http://www.w3.org/2001/XMLSchema#string